WC
SGNT

Wexford Capital’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History

Wexford Capital’s Portfolio SGNT Stock Details SGNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-95,890
Closed -$1.96M – 298
2013
Q3 		$1.96M Buy
+95,890
New +$2.13M 0.16% 79

Other funds holding SGNT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.29B AUM 53.44% 1-Year Est. Return
NIMC
NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Wexford Capital's SGNT Position: Q4 2013 in Review

Wexford Capital sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q4 2013, closing a stake of 95,890 shares — an estimated $1.96M sold.

Wexford Capital first reported a position in SGNT in Q3 2013 and held it in 1 quarter. The position peaked at $1.96M in Q3 2013. 99 funds tracked by Wall St. Rank hold SGNT as of Q4 2013.

  • Wexford Capital reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q4 2013 after selling out during the quarter.
  • Wexford Capital sold 95,890 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q4 2013, an estimated $1.96M.
  • Wexford Capital first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q3 2013 and held it in 1 quarter.
  • Wexford Capital's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $1.96M in Q3 2013.
  • 99 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q4 2013.

Based on Wexford Capital's 13F filing for Q4 2013, filed 14 Feb 2014.